Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 19/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14004263 | 0.94 | CALCRL (0.92) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL30231967 | 0.94 | CALCRL (0.92) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL3763200 | 0.94 | CALCRL (0.92) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL13053544 | 0.92 | CALCRL (1.00) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL3607829 | 0.92 | CALCRL (1.00) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL3768699 | 0.92 | CALCRL (0.86) | CALCRLCYP3A4CYP2D6RAMP1 | |
| SCHEMBL3754417 | 0.91 | CALCRL (0.92) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL30231385 | 0.90 | CALCRL (0.93) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL3762519 | 0.90 | CALCRL (0.93) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL14526789 | 0.89 | CALCRL (0.79) | CALCRLCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314883-B2 | Anti-migraine treatments | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314883-B2 | Anti-migraine treatments | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BDKRB2, PTGIR, CALCRL | CALCRL 3/4885CYP3A4 3634/4885CYP2D6 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.